graft versus host disease (GVHD) | Page 6 | Aplastic Anemia & MDS International Foundation Return to top.

graft versus host disease (GVHD)

Virtual March for Marrow 5K Run & Walk Washington DC 2021

Patients, family members, friends and advocates, sign up, tell your story, create a team, and set a goal to support AAMDSIF!

Anywhere you and your friends choose to, walk, run, cycle – in a park, through your neighborhood, or on a treadmill – anytime leading up to or during the day of the 24th.

Event Date: 
Sun, 10/24/2021 - 10:00am (EDT)
Community Event Type: 

FDA approves belumosudil for chronic graft-versus-host disease

On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

Efficacy was evaluated in KD025-213 (NCT03640481), a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic GVHD who were treated with belumosudil 200 mg taken orally once daily.

Teen Support Group for Bone Marrow Failure Diseases

Event Date: 
Thu, 08/26/2021 - 5:30pm (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients and siblings ages 13-17. The group is hosted by AAMDSIF and will be monitored to ensure the privacy and safety of our participants. Parent/Guardian permission is required to participate in the group. 

Constandina Herbert, MN, RN, BMTCN

Herbert, Constandina
Nursing Supervisor
Fred Hutchinson Cancer Research Center

Constandina Herbert, MN, RN, BMTCN is the Nursing Supervisor, Blood and Marrow Transplant Clinic at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Ms. Herbert works with patients, families, and caregivers as they navigate the transplant process. 

Share with addtoany.com.